Use of a polyclonal antibody for the determination of the prognostic value of c-erbB-2 protein over-expression in human breast cancer

Acta Oncologica

Volumn 35, Issue 1, 1996, Pages 23-30

  Terrier, Philippe ^a   Mouriesse, Hélène ^a   Loridon, Brigitte ^b   Gotteland, Marianne ^b   May Levin, Françoise ^a   Delarue, Jean Claude ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Institut de Recherches Scientifiques sur le Cancer   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; POLYCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS;

ANIMALS; ANTIBODIES, NEOPLASM; BREAST NEOPLASMS; CARCINOMA; COLORING AGENTS; EPITOPES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LINEAR MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PARAFFIN EMBEDDING; PROGNOSIS; RABBITS; RECEPTOR, ERBB-2; RISK FACTORS; RNA, MESSENGER;

EID: 0029976104     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609098475     Document Type: Article

References (35)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER 2/neu oncogene. Science 1987; 235: 177-82.
2. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. ERBB2 amplification in breast cancer with high rate of proliferation. Oncogene 1991; 6: 137-43.
3. May E, Mouriesse H, May-Levin F, Qian JF, May P, Delarue JC. Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer 1990; 62: 430-5.
4. Rilke F, Colnaghi ML, Cascinelli N, et al. Pronostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991; 49: 44-9.
5. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER 2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
6. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER 2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120-8.
7. Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-co-amplification units: hst.1/int.2 c-erbB-2/ear-1. Cancer Res 1989; 49: 3104-8.
8. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989; 49: 2087-90.
9. Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS, Altman DG. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 1988; 58: 488-52.
10. Van de Vijver MJ, Peterse JL, Maoi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in Stage Il breast cancer. N Engl J Med 1988; 319: 1239-45.
11. Zhou DJ, Ahuji H, Cline MJ. Proto-oncogene abnormalities in human breast cancer. c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene 1989; 4: 105-8.
12. National Institute of Health: Consensus development conference statement treatment of early stage breast cancer. Bethesda, Md: National Institute of Health, 1990.
13. Naber SP, Tsutsumi Y, Yin S, et al. Strategies for the analysis of oncogene overexpression. Am J Clin Pathol 1990; 94: 125-36.
14. Slamon DJ, Press MJ, Godolphin W, et al. Studies of the HER 2/neu proto-oncogene in human breast cancer. Cancer Cells 1989; 7: 371-84.
15. Troalen F, Maudelonde T, Montcourrier P, Bohuon C, Delarue JC. Characterization of two monoclonal antibodies against the COOH-terminal part of the human epidermal growth factor receptor and potential clinical use. J Immunol Methods 1991; 143: 175-86.
16. May E, Mouriesse H, May-Levin F, Contesso G, Delarue JC. A new approach allowing an early prognosis in breast cancer: the ratio of estrogen receptor (ER) ligand binding activity to the ER-specific mRNA level. Oncogene 1989; 4: 1037-42.
17. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Measurem 1960; 20: 37-46.
18. Allred DC, Clark GM, Tandon AK, et al. HER 2/neu in node negative breast cancer: prognostic significance of overpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599-605.
19. Borg A, Tandon AK, Sigurdsson H, et al. HER 2/neu amplification predicts poor survival in node positive breast cancer. Cancer Res 1990; 50: 4332-7.
20. Gasparini G, Gullick WJ, Bevilacqua P, et al. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy and conventional pathologic features. J Clin Oncol 1992; 10: 686-95.
21. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049-56.
22. Lovekin C, Ellis IO, Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991; 63: 439-43.
23. O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 1991; 63: 444-6.
24. Thor AD, Schwartz LH, Koerner FC, et al. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 1989; 49: 7147-52.
25. Toikkanen S, Helin H, Joensuu H. Prognostic significance of HER 2 oncoprotein expression in breast cancer: A 30-year follow-up. J Clin Oncol 1992; 10: 1044-8.
26. Tsuda H, Hirohashi S, Shimosato Y, et al. Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients. Jpn J Cancer Res 1990; 81: 327-32.
27. Walker RA, Gullick WJ, Varley JM. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer 1989; 60: 426-9.
28. Winstanley J, Cooke T, Murray GD, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991; 63: 447-50.
29. Gullick WJ, Berger MS, Bennett PLP, et al. Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer 1987; 40: 246-54.
30. Berger MS, Locher GW, Saurer S, et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988; 48: 1238-43.
31. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103-12.
32. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991; 49: 650-5.
33. McCann AH, Dervan PA, O'Regan M, et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 1991; 51: 3296-303.
34. De Potter CT, Beghin C, Makar AP, Vandekerckhove D, Roels HJ. The neu-oncogene protein as a predictive factor for hæmatogenous metastases in breast cancer patients. Int J Cancer 1990; 45: 55-8.
35. Baak JPA, Chin D, Van Diest PJ, Ortiz R, Matze-Cok P, Bacus SS. Comparative long-term prognostic value of quantitative HER 2/neu protein expression, DNA ploidy and morphometric and clinical features in paraffin. Embedded invasive breast cancer. Lab Invest 1991; 64: 215-23.